Omalizumab Administration and Safety Considerations

Administration Safety

• Omalizumab administration carries a small risk (0.2%) of anaphylaxis, and the medication should be administered by a healthcare provider trained to recognize and treat anaphylaxis, with patients observed for 30 minutes after each injection (2 hours for the first 3 injections), and having access to an epinephrine autoinjector, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2, 3, 4
• The American Academy of Allergy, Asthma, and Immunology recommends that patients receiving omalizumab should be monitored for signs of anaphylaxis, and that healthcare providers should be trained to recognize and treat anaphylaxis 1, 3